PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schommers, P.* ; Kim, D.S.* ; Schlotz, M.* ; Kreer, C.* ; Eggeling, R.* ; Hake, A.* ; Stecher, M.* ; Park, J.* ; Radford, C.E.* ; Dingens, A.S.* ; Ercanoglu, M.S.* ; Gruell, H.* ; Odidika, S.* ; Dahlhaus, M.* ; Gieselmann, L.* ; Ahmadov, E.* ; Lawong, R.Y.* ; Heger, E.* ; Knops, E.* ; Wyen, C.* ; Kümmerle, T.* ; Römer, K.* ; Scholten, S.* ; Wolf, T.* ; Stephan, C.* ; Suárez, I.* ; Raju, N.* ; Adhikari, A.* ; Esser, S.* ; Streeck, H.* ; Duerr, R.* ; Nanfack, A.J.* ; Zolla-Pazner, S.* ; Geldmacher, C.* ; Geisenberger, O.* ; Kroidl, A.* ; William, W.* ; Maganga, L.* ; Ntinginya, N.E.* ; Georgiev, I.S.* ; Vehreschild, J.J.* ; Hoelscher, M. ; Fätkenheuer, G.* ; Lavinder, J.J.* ; Bloom, J.D.* ; Seaman, M.S.* ; Lehmann, C.* ; Pfeifer, N.* ; Georgiou, G.* ; Klein, F.*

Dynamics and durability of HIV-1 neutralization are determined by viral replication.

Nat. Med. 29, 2763-2774 (2023)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers-persons with HIV-1 who naturally develop broad and potent nAbs-can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART). Infection with non-clade B viruses, CD4+ T cell counts <200 µl-1, being off ART and a longer time off ART were independent predictors of a more potent and broad neutralization. In longitudinal analyses, we found nAb half-lives of 9.3 and 16.9 years in individuals with no- or low-level viremia, respectively, and 4.0 years in persons who newly initiated ART. Finally, in a potent HIV-1 neutralizer, we identified lower fractions of serum nAbs and of nAb-encoding memory B cells after ART initiation, suggesting that a decreasing neutralizing serum activity after antigen withdrawal is due to lower levels of nAbs. These results collectively show that HIV-1-neutralizing responses can persist for several years, even at low antigen levels, suggesting that an HIV-1 vaccine may elicit a durable nAb response.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
82.900
0.000
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Immunodeficiency-virus Type-1; Monoclonal-antibodies; Serum; Responses; Escape; Broad; Panel; Association; Specificity; Repertoire
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 1078-8956
e-ISSN 1546-170X
Journal Nature medicine
Quellenangaben Volume: 29, Issue: 11, Pages: 2763-2774 Article Number: , Supplement: ,
Publisher Nature Publishing Group
Publishing Place New York, NY
Reviewing status Peer reviewed
Institute(s) Research Unit Global Health (UGH)
POF-Topic(s) 30205 - Bioengineering and Digital Health
Research field(s) Enabling and Novel Technologies
PSP Element(s) G-540001-003
Grants Universität zu Köln
DOI 10.1038/s41591-023-02582-3
WOS ID 001205211300011
WOS ID 001173011000007
WOS ID 001104323200011
Scopus ID 85176455394
PubMed ID 37957379
Erfassungsdatum 2023-11-28
[➜Report correction]